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AbstrAct
Objectives The aim of this research is to evaluate the 
relative cost-effectiveness of functional and anatomical 
strategies for diagnosing stable coronary artery disease 
(CAD), using exercise (Ex)-ECG, stress echocardiogram 
(ECHO), single-photon emission CT (SPECT), coronary CT 
angiography (CTA) or stress cardiacmagnetic resonance 
(C-MRI).
Setting Decision-analytical model, comparing strategies 
of sequential tests for evaluating patients with possible 
stable angina in low, intermediate and high pretest 
probability of CAD, from the perspective of a developing 
nation’s public healthcare system.
Participants Hypothetical cohort of patients with pretest 
probability of CAD between 20% and 70%.
Primary and secondary outcome measures The 
primary outcome is cost per correct diagnosis of CAD. 
Proportion of false-positive or false-negative tests and 
number of unnecessary tests performed were also 
evaluated.
Results Strategies using Ex-ECG as initial test were the 
least costly alternatives but generated more frequent 
false-positive initial tests and false-negative final 
diagnosis. Strategies based on CTA or ECHO as initial 
test were the most attractive and resulted in similar 
cost-effectiveness ratios (I$ 286 and I$ 305 per correct 
diagnosis, respectively). A strategy based on C-MRI was 
highly effective for diagnosing stable CAD, but its high cost 
resulted in unfavourable incremental cost-effectiveness 
(ICER) in moderate-risk and high-risk scenarios. Non-
invasive strategies based on SPECT have been dominated.
Conclusions An anatomical diagnostic strategy based 
on CTA is a cost-effective option for CAD diagnosis. 
Functional strategies performed equally well when based 
on ECHO. C-MRI yielded acceptable ICER only at low 
pretest probability, and SPECT was not cost-effective in 
our analysis.
IntroductIon
Proper evaluation and diagnosis of coronary 
artery disease (CAD) is an essential part of 
public health strategies, given the impor-
tance of CAD in worldwide morbidity and 
mortality.1 When a patient presents with 
chest pain symptoms, his or her probability 
of having CAD can vary from less than 10% 
to more than 90%, depending on clinical 
and epidemiological characteristics.2 In the 
frequent cases with intermediate pretest 
probability, additional diagnostic tests can aid 
in clinical decision making and risk stratifica-
tion.
Nowadays, several non-invasive tests for 
diagnosing CAD are widely available and 
have varying accuracy and costs. In Brazil, 
the Unified National Health System (Sistema 
Único de Saúde—SUS) currently reimburses 
exercise (Ex)-ECG, stress echocardiography 
(ECHO) and nuclear stress testing (SPECT) 
but not coronary CT angiography (CTA) or 
stress cardiac magnetic resonance (C-MRI).3
Recommendations for diagnostic test 
selection are not uniform in current prac-
tice guidelines,2 4 5 and in many, if not most 
occasions, the choice among these tests is 
determined primarily by individual physician 
preference and/or local availability. This may 
overlook several other important factors, 
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Research
Strengths and limitations of this study
 ► There is no evidence that diagnostic test selection 
impacts cardiovascular event rates in stable 
coronary artery disease (CAD), and economic results 
may help guide choice among tests.
 ► Our results show that incorporating coronary CT into 
the Brazilian Public Health System would add a cost-
effective option for CAD diagnosis.
 ► Among currently available technologies, the 
demonstration that stress echocardiography is 
more cost-effective than single-photon emission CT 
from this perspective may improve public resource 
allocation.
 ► Cost-effectiveness results are useful to establish 
the ‘standard’ test for routine use, but flexibility in 
the choice among tests is still important, allowing 
physicians to select the best strategy for each 
particular case.
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from the efficacy of each test for a given pretest proba-
bility to economic issues such as added cost per diagnosis 
when an inexpensive test such as Ex-ECG is systematically 
replaced by a more expensive, although more accurate 
test such as SPECT.
Recently published data from a large randomised trial 
shows that anatomical testing using CTA results in similar 
long-term event rates as functional testing with Ex-ECG, 
SPECT or ECHO.6 These results should increment the 
importance of economic data in the decision-making 
process for test selection.
We aimed to compare the cost-effectiveness, measured 
as cost per correct diagnosis, of various functional and 
anatomical testing strategies for patients with suspected 
CAD. This information can supplement efficacy data in 
decision-makers’ choice of approved exams for health 
plans, and provide grounds for the development of 
nationwide protocols for the management of stable 
angina.
Methods
Model
We built a decision-analytical model that compares 
different strategies for evaluating patients with possible 
stable angina from the public health system’s perspec-
tive. Figure 1 schematically depicts the model structure; a 
more detailed, technical depiction of the model structure 
is available in the online supplementary figure A. The 
model, developed in Treeage Pro 2013, is considered a 
hypothetical cohort of patients with pretest probability of 
CAD between 20% and 70%.
We defined eight functional strategies and three anatom-
ical strategies based on clinically realistic sequences of 
tests (table 1); in each strategy, the patient undergoes 
an initial test, moving on to further testing in case of 
positive or indeterminate results. Negative results do not 
generate additional tests. Strategy 1, for example, begins 
with Ex-ECG as a first test. Patients with positive or inde-
terminate results undergo the second test, ECHO; if the 
second test is positive or indeterminate, patients move on 
to invasive coronary angiography (CA) as the final test. In 
scenarios with high pretest probability, we also considered 
strategies that use CA as first test, reserving non-invasive 
test for equivocal CA results, such as coronary lesions of 
unknown haemodynamic significance.
outcomes
The model ends with a test result (positive or negative), 
potentially true or false depending on the accuracy of the 
tests, resulting in final costs per correct diagnosis. There 
is also a small risk of death due to test-related adverse 
events (table 2).
data sources
After systematic review of previous studies of accuracy, we 
used available data from published meta-analyses of test 
performance and risks to populate the model (table 2).
Brazilian National Health System (Sistema Único de 
Saúde—SUS) 2013 reimbursement rates were the source 
of costs for diagnostic tests for currently reimbursed tests3; 
costs of CTA and MRI were estimated based on rates for 
currently reimbursed tests (chest CT and rest C-MRI), 
inflated proportionally to cost differences among these 
tests in the private sector7 (table 2).
All costs were converted from Brazilian real to interna-
tional dollars (I$), using the World Bank’s latest available 
purchasing power parity conversion factor of 1.89.8
Assumptions
We assumed 100% sensitivity and specificity for CA, since 
it is the gold standard for diagnosing coronary artery 
Figure 1 Schematic representation of model structure.
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disease. Another assumption was that for the last test in 
any strategy, whether it is CA (as in strategies 1–9) or a 
non-invasive test (as in strategies 10–11), the probability 
of indeterminate results is zero.
We assumed myocardial infarction (MI) as an example 
of serious investigation-related complication, and 
applied SUS data regarding average national costs for 
MI admissions in 2012, I$ 1670,3 as reference for cost of 
complications (including death).
Separate analyses were performed, with low (20%), 
medium (50%) and high (70%) pretest probabilities of 
CAD, corresponding to the range of pretest probability 
in which non-invasive tests are most useful, according to 
the American Heart Association’s guidelines on stable 
angina.2
sensitivity analysis
Aiming to test the robustness of the model and the weight 
of individual parameters on results, during sensitivity anal-
ysis, we varied test accuracies and rates of complications 
and indeterminacy around their 95% CIs. Alternative 
costs of tests ranged from half the original values to 
double those values.
In addition to one-way and two-way sensitivity analyses, 
we performed probabilistic sensitivity analysis with 10 000 
samples, with simultaneous variation of model parame-
ters around their CIs. We used beta distributions for test 
accuracies and gamma distributions for costs.
Additionally, taking into account that in some situa-
tions, CA may be considered an unacceptable first test 
due to patient or physician preferences, we considered an 
alternative scenario excluding strategies that begin with 
CA (strategies 10 and 11).
Willingness to pay
There is no broadly accepted willingness-to-pay (WTP) 
threshold for additional costs per correct diagnosis. For 
results per quality-adjusted life years, the WHO recom-
mends a WTP threshold between one and three times a 
nation’s gross domestic product (per capita for middle-in-
come countries.9 For Brazil, these figures are I$ 11 700 to 
35 200 per quality-adjusted life-year (QALY).
Table 1 Test sequence in each modelled strategy
First test Second test Third test
Strat. 1 Exercise ECG Stress echocardiography Coronary angiography
Strat. 2 Exercise ECG Coronary CT angiography Coronary angiography
Strat. 3 Exercise ECG SPECT Coronary angiography
Strat. 4 Exercise ECG Coronary angiography
Strat. 5 SPECT Coronary angiography
Strat. 6 Stress echocardiography Coronary angiography
Strat. 7 Stress echocardiography Coronary CT angiography Coronary angiography
Strat. 8 Stress cardiac MRI Coronary angiography
Strat. 9 Coronary CT angiography Coronary angiography
Strat. 10* Coronary angiography Stress echocardiography
Strat. 11* Coronary angiography SPECT
*Strategies 10 and 11, in which invasive coronary angiography is the first test, are only considered in scenarios with high pretest probability.
SPECT, single-photon emission CT .
Table 2 Characteristics of tests, range of values used in sensitivity analysis and costs
Test
Sensitivity  
(%) (range)
Specificity  
(%) (range)
Indeterminate  
(%)
Mortality  
(‰)
Cost  
(I$) Sources
Ex-ECG 65 (42–92) 67 (43–83) 18 0.05 16 3 16 17
ECHO 85 (83–87) 77 (74–80) 15 0.05 87 3 18 19
SPECT 87 (84–88) 64 (60–76) 6.9 0.05 419 3 18 19
CTA 88 (83–92) 87 (80–92) 2 0.01 101 3 20–22
MRI 89 (88–94) 80 (75–87) 5 0.01 200 3 19 23
CA 100 100 10 0.2 325 Assumption3 4 24
CA, invasive coronary angiography; CTA, CT coronary angiogram; ECHO, stress echocardiogram; Ex-ECG, exercise ECG; SPECT, single-
photon emission CT. 
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Since per-diagnosis results could be considered to be 
of a lower magnitude than per-QALY results, we did not 
make any assumption regarding lower limit of WTP but 
rather chose to describe the main findings.
results
Table 3 shows average costs, accuracy and comparative 
cost-effectiveness results from testing a population with 
low (20%) to high (70%) pretest probability of CAD 
with each diagnostic strategy. In Figure 2, cost-effective-
ness results for each pretest probability are illustrated, 
excluding dominated strategies.
low pretest probability (20%)
With low probability of CAD, strategy 2 (Ex-ECG → CTA 
→ CA) was the least costly strategy, with a mean cost per 
diagnosis of I$ 135 while retaining good overall perfor-
mance (92.6% correct diagnosis, 5% invasive CA in 
patients without CAD). Upgrading to strategy 9 (CTA → 
CA) increases effectiveness to 97.6% of correct diagnosis, 
with mean cost per diagnosis I$ 200 and incremental 
cost-effectiveness ratio (ICER) of I$ 1420. Substituting 
strategy 9 with strategy 8 (C-MRI → CA) modestly 
increases diagnostic accuracy to 97.9% but raises mean 
cost per diagnosis to I$ 320, resulting in a much higher 
ICER of I$ 47 800.
The other strategies were either absolutely or relatively 
dominated. However, strategy 1 (Ex-ECG → ECHO → 
CA) had accuracy results that were practically identical to 
strategy 2 (92.4% correct diagnosis), with mean cost per 
diagnosis only marginally higher, I$ 150.
Moderate pretest probability (50%)
In moderate CAD probability scenario, strategy 2 (Ex-ECG 
→ CTA → CA) remained the least costly strategy, at I$ 
230 per correct diagnosis; however, in this scenario, this 
strategy resulted in a relatively low overall accuracy of 
81%, with over 18% false negative final diagnoses. Strategy 
4 (Ex-ECG → CA) improves overall accuracy to 86%, with 
14% false negative results and costs I$ 240 per correct 
diagnosis. Resulting in an ICER versus strategy 2 of I$ 415.
In this range of pretest probability, the strategy based 
on CTA coronary angiography as initial test (strategy 
9) yields significantly better outcomes, with 94% overall 
accuracy. Mean cost per diagnosis is I$ 285, resulting in 
an ICER versus strategy 4 of I$ 750 per correct diagnosis. 
Strategy 8, based on C-MRI, raises accuracy to 95%, while 
increasing mean cost per diagnosis to I$ 410. ICER for 
strategy 8 versus strategy 9 is I$ 17 800 per correct diag-
nosis.
Remaining strategies have been dominated by strate-
gies 2, 4, 9 and 10. Once again, it should be noted that 
strategy 6 (Echo → CA) yields accuracy results very close 
to the ones obtained with strategy 9 (93.6%) at a margin-
ally higher mean cost per diagnosis of I$ 305.
high pretest probability (70%)
With a higher prevalence of CAD, strategies that involve 
two non-invasive tests before CA are dominated by strategy 
Table 3 Base-case results for different pretest probabilities. Dominated strategies not shown, except when significant 
uncertainty regarding dominance on sensitivity analysis
Pretest 
probability Strategy
Avg cost 
per patient 
(I$)
C-E
(I$/diag)
ICER
(I$/diag)
Accuracy 
(%)
FN
(%)
Deaths 
(%)
Invasive 
CA (%)
Negative 
invasive 
CA (%)
Low 2 (Ex-ECG→CTA → CA) 125 135 - 93 7.4 0.009 18 5
1 (Ex-ECG → ECHO → CA) 141 153 - 92 7.6 0.012 25 12
9 (CTA → CA) 197 202 1420* 98 2.4 0.007 29 12
8 (C-MRI → CA) 315 322 47 800† 98 2.1 0.008 37 19
Moderate 2 (Ex-ECG → CTA → CA) 188 231 - 81 18.5 0.013 35 3
4 (Ex-ECG → CA) 205 240 415‡ 86 14.3 0.017 58 23
9 (CTA → CA) 269 286 750§ 94 5.9 0.011 51 7
6 (ECHO → CA) 286 305 - 94 6.4 0.017 61 17
8 (C-MRI → CA) 385 407 17 800† 95 5.2 0.012 57 12
High 4 (Ex-ECG → CA) 222 278 - 80 20.1 0.018 63 14
9 (CTA → CA) 317 345 790§ 92 8.2 0.014 66 4
6 (ECHO → CA) 320 351 - 91 8.9 0.019 71 10
10 (CA → ECHO) 373 381 273† 98 1.7 0.02 100 30
*ICER vs strategy 1.
†ICER vs strategy 9.
‡ICER vs strategy 2.
§ICER vs strategy 4.
Avg, average; CA, invasive coronary angiography; C-E, cost-effectiveness; C-MRI, cardiac MRI;  CTA, CT coronary angiogram; ECHO, stress 
echocardiogram; Ex-ECG, exercise ECG; FN, false-negative; ICER, incremental cost-effectiveness ratio. ; 
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4 (Ex-ECG → CA), which results in 80% correct identifi-
cation at I$ 280 per diagnosis. However, in this range of 
CAD risk, strategy 4 results in 20% false-negative results, 
seriously hindering its usefulness in practice.
If strategies with false-negative rates above 20% (1-4) are 
excluded from analysis, strategy 9 (CTA → CA) emerges 
as an attractive option, with overall accuracy of 92% and 
mean cost per diagnosis of I$ 345. Strategy 6 (Echo → 
CA) results in practically identical effectiveness (91%) at 
a somewhat higher cost per diagnosis of I$ 400.
A strategy based on invasive CA as first test (strategy 10) 
results in 98% accuracy, mean cost per diagnosis I$ 346 
and ICER I$ 273 versus strategy 9.
sensitivity analysis, scenario analysis and radiation 
exposure
In one-way sensitivity analysis, the choice between CTA 
and ECHO-based strategies was sensitive to procedure 
costs and test sensitivity. For instance, in low probability 
scenarios, CTA dominates ECHO if it costs less than I$ 
129, has higher cost and higher effectiveness with costs 
between I$ 129 and 182 and is extensively dominated 
by ECHO at higher costs. With high pretest probability, 
ECHO is the preferred non-invasive method if it costs up 
to I$ 56; and at its maximum price, ECHO is dominated 
by CTA.
Variation in cost and accuracy of other tests modified 
cost per diagnosis for each strategy but did not alter base-
case results to the extent of changing preferred strategies.
In probabilistic sensitivity analysis, there was significant 
overlap between CTA and ECHO in terms of cost-effec-
tiveness, demonstrating a high level of uncertainty as to 
which of the two strategies would be preferred (Figure 3).
In the alternative scenario that excludes CA as an initial 
test, even in the high pretest probability group, strategy 
8, based on C-MRI as first test, becomes the strategy with 
highest accuracy, with an ICER versus strategy 9 (CTA → 
CA) slightly above $12 200 with 70% pretest probability.
Focusing on currently available imaging modalities, 
we performed two-way sensitivity analysis on the choice 
between ECHO-based and SPECT-based strategies, which 
showed ECHO-based strategies to be dominant across 
the defined spectrum of sensitivity analysis. SPECT-based 
strategies are preferred only if the cost of SPECT is no 
more than 10% higher than the cost of ECHO.
Figure 2 Base-case cost-effectiveness results for predefined risk categories. Strategies 1–4 excluded from high-
probability analysis (see text for details). CA, invasive coronary angiography; CTA, CT coronary angiogram; ECHO, stress 
echocardiogram; Ex-ECG, exercise ECG; SPECT, single-photon emission CT.
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Average radiation dose per patient varied between 3.9 
mSv for strategy 1 (Ex-ECG → ECHO → CA) and 16.4 
mSv for strategy 5 (SPECT → CA). For strategy 9, based 
on CTA, mean exposure was 15.1 mSv, and for strategy 8, 
based on C-MRI, it was 5.7 mSv (see online supplemen-
tary table A).
dIscussIon
Significant interest has been placed on the choice between 
functional and anatomical strategies for CAD diag-
nosis. In the management of acute coronary syndrome, 
CTA outperformed functional testing in three clinical 
trials.10–12 However, in stable CAD, randomised data on 
the clinical impact of selecting a functional or anatomical 
strategy have only recently been published.
In the PROMISE trial,6 an anatomical strategy based on 
CTA as initial test resulted in similar clinical outcomes 
over 2 years when compared with functional testing. The 
CTA strategy, probably due to its high sensitivity, resulted 
in a lower rate of invasive CA with no evidence of CAD 
in the first 90 days. Coronary revascularisation was more 
frequent with CTA, but long-term clinical significance of 
this finding is uncertain.
This similar performance of anatomical and functional 
strategies should prompt physicians and decision makers 
to look beyond clinical outcomes in the selection of tests, 
taking into account information such as cost-effectiveness, 
resource use and environmental impact. Recent studies 
suggest CTA may be a cost-effective option in developed 
countries.13–15
In this study, we performed a cost-effectiveness analysis 
to assess currently available strategies for investigating 
chest pain in Brazil, and to compare them with new ones, 
that could become available on inclusion of CTA and 
C-MRI among reimbursed tests.
Our study showed that, from the economic perspective, 
the choice of functional test (Ex-ECG, ECHO, SPECT or 
C-MRI) influences whether a functional or anatomical 
strategy would be preferable.
The least costly diagnostic strategies are conservative 
ones, using Ex-ECG as a ‘gatekeeper’, and proceeding to 
a second round of non-invasive tests when results are posi-
tive. These low-cost strategies have the disadvantage of 
generating a larger number of false-positive initial tests, 
thus subjecting patients without CAD to additional tests. 
Furthermore, their performance deteriorates as pretest 
probability rises, so that at 70% pretest probability their 
false-negative rate is above 20%. Therefore, such strate-
gies may be an option for constrained budgets or lack of 
alternatives, but only when pretest probability is low or 
moderate (≤50%).
As pretest probability increased, costs per correct 
(positive or negative) diagnosis becomes higher for strat-
egies based on sequential tests, since positive initial tests 
Figure 3 Scatterplot of incremental cost-effectiveness of strategy 9 (CTA-CA) versus strategy 6 (ECHO-CA). ECHO, stress 
echocardiogram; CTA, CT coronary angiogram; CA, invasive coronary angiography. Dotted line represents willingness-to-pay 
threshold; ellipse contains 95% of outputs.
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are more frequent, leading to further testing in more 
patients. This is particularly true for conservative strate-
gies that require two non-invasive tests before proceeding 
to invasive CA. Strategies based on CTA and ECHO as 
initial test, result in almost superimposable cost-effective-
ness results. These strategies would increase accuracy, 
at an ICER versus Ex-ECG-based strategies well below I$ 
11 909 per correct diagnosis. This makes them attractive 
options across the entire spectrum of pretest probabili-
ties.
Diagnostic strategies based on C-MRI showed to be 
highly effective, but their relatively high (estimated) 
cost resulted in unfavourable ICERs in moderate-risk 
and high-risk scenarios. If C-MRI costs could be reduced 
to figures lower than I$ 200 estimated, it could become 
cost-effective enough to recommend for widespread 
implementation in SUS. Nonetheless, it is important to 
emphasise that, for this cost, availability and acquisition 
values were not taken into account.
Non-invasive strategies based on SPECT generated 
consistently unfavourable results due to the high cost of 
SPECT when compared with other non-invasive tests and 
have been dominated in all scenarios. In addition, radi-
ation-related risks were not included in our short-term 
model because potential effects of radiation exposure 
take more than a decade to manifest. Still, this could be 
an additional cause for concern regarding widespread 
use of tests such as SPECT and CTA.
Our study’s main limitation is that, since public health 
system does not reimburse CTA and C-MRI, we had to 
estimate procedure costs from private practice. In case 
of incorporation of these tests into the public system, 
actual reimbursement values may vary, although we did 
not expect significant discrepancy based on previous 
cases. Still, our results were robust even when we halved 
or doubled the value of our initial cost estimate.
Current practice in Brazil usually prioritises SPECT-
based over ECHO-based strategies for diagnosing CAD. 
Based on the national database, in the year 2013, the 
Brazilian public health system reimbursed over 1 00 000 
SPECT tests and less than 19 000 ECHO tests for outpa-
tients.3 Our results suggest that ECHO-based strategies 
should be more widely employed in SUS, especially 
considering their absence of radiation and low costs for 
implementation and maintenance.
Updating reimbursement values for ECHO may stimu-
late the availability of this test in the public health system, 
and seems justified, since our sensitivity analysis showed 
that ECHO would remain more cost-effective than SPECT 
even with costs up to four times higher than current rates.
conclusIons
For the diagnosis of stable CAD, strategies based on 
exercise ECG are the least expensive, but their lower 
effectiveness means they are best suited for constrained 
budgets, and only when pretest probability is low or 
moderate.
Regarding technologies that are currently available in 
SUS, stress echocardiography is more cost-effective than 
SPECT and should generally be preferred if available.
Incorporation of coronary CT into SUS would add a 
cost-effective option for CAD diagnosis. Stress C-MRI 
yielded acceptable ICER only at low pretest probability. 
Our results suggest that the immediate incorporation of 
coronary CT into SUS is advisable if actual test costs can 
match our estimated cost of I$ 100 per test. Incorporation 
of stress C-MRI should be considered only if its costs can 
be reduced to values significantly lower than our estimate 
of I$ 200.
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